Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management
Academic Article
Publication Date:
2020
Short description:
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management / Bruni, C., Allanore, Y., Clementi, M., Dagna, L., Damjanov, N.S., De Paulis, A., Denton, C.P., Distler, O., Fox, D., Furst, D.E., Khanna, D., Krieg, T., Kuwana, M., Lee, E.B., Li, M., Pillai, S., Wang, Y., Zeng, X., Taliani, G., Matucci-Cerinic, M.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 79:6(2020), pp. 724-726. [10.1136/annrheumdis-2020-217407]
abstract:
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
Iris type:
1.1 Articolo in rivista
List of contributors:
Bruni, C.; Allanore, Y.; Clementi, M.; Dagna, L.; Damjanov, N. S.; De Paulis, A.; Denton, C. P.; Distler, O.; Fox, D.; Furst, D. E.; Khanna, D.; Krieg, T.; Kuwana, M.; Lee, E. B.; Li, M.; Pillai, S.; Wang, Y.; Zeng, X.; Taliani, G.; Matucci-Cerinic, M.
Published in: